title: Plasma miRNA-506 as a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma.
abstract: BACKGROUND MicroRNAs (miRNAs) are responsible for regulating proliferation, differentiation, apoptosis, invasion, and metastasis in tumor cells. miRNA-506 is abnormally expressed in multiple tumors, indicating that it might be oncogenic or tumor-suppressive. However, little is known about the association between miRNA-506 expression and esophageal squamous cell carcinoma (ESCC). MATERIAL AND METHODS We examined the expression of miRNA-506 in the plasma of ESCC patients using quantitative real-time polymerase chain reaction (qRT-PCR) to determine the association between miRNA-506 expression and clinicopathological features of ESCC. ROC curves were produced for ESCC diagnosis by plasma miRNA-506 and the area under curve was calculated to explore its diagnostic value. RESULTS Average miRNA-506 expression levels were remarkably higher in the plasma of ESCC patients than in healthy volunteers (P<0.001). The expression of miRNA-506 in the plasma was closely associated with lymph node status (P=0.004), TNM stage (P=0.031), and tumor length (P<0.001). According to ROC curves, the area under the curve for plasma miRNA-506 was 0.835, indicating statistical significance for ESCC diagnosis by plasma miRNA-506 (P<0.001). Kaplan-Meier analysis showed that patients with high miRNA-506 expression had significantly shorter survival time than those with low miRNA-506 expression. Cox regression analysis demonstrated that T stage, N stage, tumor length, and miRNA-506 expression levels were significantly correlated with prognosis in ESCC patients. CONCLUSIONS miRNA-506 can serve as an important molecular marker for diagnosis and prognostic prediction of ESCC.
authors.affiliation: Department of Radiation Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China (mainland).
authors.forename: Shu-Ping
authors.initials: SP
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China (mainland).
authors.forename: Hong-Xin
authors.initials: HX
authors.lastname: Su
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China (mainland).
authors.forename: Da
authors.initials: D
authors.lastname: Zhao
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China (mainland).
authors.forename: Quan-Lin
authors.initials: QL
authors.lastname: Guan
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000235:genetics* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; C561508:MIRN506 microRNA, human; D035683:MicroRNAs